{"prompt": "['Carbomer and Carboxymethylcellulose', '209510', 'Clinical Protocol V1.0', 'In addition, the investigator will inform GSK CH immediately of any urgent safety measures', 'taken by the investigator to protect the study subjects against any immediate hazard, and of any', 'serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.', '13.4', 'Posting of Information on Publicly Available Clinical Trial', 'Registers', 'Study information from this protocol will be posted on publicly available clinical trial registers', 'before enrollment of subjects begins in accordance with applicable GSK CH processes.', 'GSK intends to make anonymized subject-level data from this trial available to external', 'researchers for scientific analyses or to conduct further research that can help advance medical', 'science or improve patient care. This helps ensure the data provided by trial participants are', 'used to maximum effect in the creation of knowledge and understanding', '13.5', 'Provision of Study Results to Investigators', 'Where required by applicable regulatory requirements, an investigator signatory will be', 'identified for the approval of the clinical study report. The investigator will be provided', 'reasonable access to statistical tables, figures, and relevant reports and will have the opportunity', 'to review the complete study results at a GSK CH site or other mutually-agreeable location.', 'GSK CH will also provide the investigator with the full summary of the study results. The', 'investigator is encouraged to share the summary results with the study subjects, as appropriate.', 'The procedures and timing for public disclosure of the results summary and for development of', 'a manuscript for publication will be in accordance with GSK CH Policy.', 'A manuscript will be progressed for publication in the scientific literature if the results provide', 'important scientific or medical knowledge.', '13.6', 'Records Retention', 'Following closure of the study, the investigator must maintain all site study records (except for', 'those required by local regulations to be maintained elsewhere), in a safe and secure location.', 'The records (study/ site master file) must be maintained to allow easy and timely retrieval, when', 'needed (e.g. for a GSK CH audit or regulatory inspection) and must be available for review in', 'conjunction with assessment of the facility, supporting systems, and relevant site staff.', 'Where permitted by local laws/regulations or institutional policy, some or all of these records', 'can be maintained in a format other than hard copy (e.g. microfiche, scanned, electronic);', 'however, caution needs to be exercised before such action is taken.', 'The investigator must ensure that all reproductions are legible and are a true and accurate copy', 'of the original and meet accessibility and retrieval standards, including re-generating a hard', 'copy, if required. Furthermore, the investigator must ensure there is an acceptable back-up of', 'these reproductions and that an acceptable quality control process exists for making these', 'reproductions.', \"The investigator must assure that the subject's anonymity will be maintained. On CRFs or other\", 'documents submitted to GSK CH, subjects should not be identified by their names or initials,', \"but by an identification code. The investigator should keep a separate log of subjects' codes,\", \"names and addresses. Documents not for submission to GSK CH, e.g. subjects' written consent\", 'forms, should be maintained by the investigator in strict confidence.', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 54 of 65']['Carbomer and Carboxymethylcellulose', '209510', 'Clinical Protocol V1.0', 'Records and documents, including signed ICF, pertaining to the conduct of this study must be', 'retained by the investigator for 25 years from the issue of the final Clinical Study Report (CSR)', 'or equivalent summary, unless local regulations or institutional policies require a longer', 'retention period. The minimum retention time will meet the strictest standard applicable to that', 'site for the study, as dictated by any institutional requirements or local laws or regulations, GSK', 'CH standards/procedures, and/or institutional requirements.', 'No study document should be destroyed without a prior written agreement between GSK CH', 'and the investigator. The investigator must notify GSK CH of any changes in the archival', 'arrangements, including, but not limited to, archival at an off-site facility or transfer of', 'ownership of the records in the event the investigator is no longer associated with the site.', '13.7', 'Conditions for Terminating the Study', 'Premature termination of this study may occur because of a regulatory authority decision,', 'change in opinion of the IRB/EC, or study product safety problems, or at the discretion of GSK', 'CH. In addition, GSK CH retains the right to discontinue development of carbomer and', 'carboxymethyleellulose at any time. For multicenter studies (if applicable), this can occur at', 'one or more or at all sites.', 'If a study is prematurely terminated, GSK CH will promptly notify the investigator. After', 'notification, the investigator must promptly contact all participating subjects and should assure', 'appropriate therapy/ follow-up for the subjects. As directed by GSK CH, all study materials', 'must be collected and all CRFs completed to the greatest extent possible. Where required by', 'the applicable regulatory requirements, GSK CH should inform the regulatory authority(ies)', 'and the investigator should promptly inform the IRB/EC and provide the IRB/EC a detailed', 'written explanation of the termination or suspension.', 'If the IRB/EC terminates or suspends its approval/favorable opinion of a trial, the investigator', 'should promptly notify the GSK CH and provide GSK CH with a detailed written explanation', 'of the termination or suspension.', 'Upon completion or premature discontinuation of the study, the GSK CH monitor will conduct', 'site closure activities with the investigator or site staff, as appropriate, in accordance with', 'applicable regulations including GCP, and GSK CH Standard Operating Procedures.', '14', 'REFERENCES', '207545, A bite force study assessing two currently marketed denture adhesive products', 'compared to no-adhesive control. GSK Data Held on File; 2017.', 'Ahmad M, Ibrahim DFA, Hazmi NH, et al. An investigation into the effect of denture', 'adhesives in limiting the food impaction. Malaysian Dent J. 2010;31(2):65-70.', 'Allen F, Locker D. A modified short version of the oral health impact profile for assessing', 'health-related quality of life in edentulous adults. International Journal of Prosthodontics.', '2002;15(5).', 'Atchison KA, Dolan T. Development of the geriatric oral health assessment index. J Dent', 'Edu. 1990a;54(11):680-7.', 'Atchison KA, Dolan TA. Development of the geriatric oral health assessment index. J Dent', 'Edu. 1990b;54(11):680-7.', 'Budtz - J\u00f8rgensen E. Oral mucosal lesions associated with the wearing of removable', 'dentures. Journal of Oral Pathology & Medicine. 1981;10(2):65-80.', 'Coates A. Usage of denture adhesives. Journal of dentistry. 2000;28(2): 137-40.', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 55 of 65']\n\n###\n\n", "completion": "END"}